King's contributes to European Master's Programme in Medicines Regulatory Affairs
King’s College London is working alongside the Universities of Copenhagen, Basel and Hertfordshire, to produce a common master’s programme in Medicines Regulatory Affairs. A Memorandum of Understanding has been signed, to advance the implementation of a common curriculum for this programme, aimed at drug development professionals.
Professor Brian Gennery, Director of the suite of master’s programmes in Pharmaceutical Medicine at King’s, has been part of the project team that comprises representatives from each of the universities, pharmaceutical companies and professional societies in the PharmaTrain project of the Innovative Medicines Initiative (IMI), as well as regulatory authorities across Europe.
Michel Goldman Executive Director of IMI welcomed the announcement by saying that ‘this master’s programme will help both new and existing drug development professionals to ensure their work is in line with the latest developments in regulatory affairs.’
Initially the programme is being offered by the University of Copenhagen in collaboration with Medicademy and the University of Hertfordshire in collaboration with The Organisation for Professionals in Regulatory Affairs (TOPRA). King’s is offering modules for the programme, as is the University of Basel with DIA Europe Middle East and Africa.
Professor Gennery says: 'King's College London has always been a strong supporter of PharmaTrain and we are pleased to be able to offer some of our modules for this new programme.'
The modules offered by King’s are: Statistics & Data Management, Advanced Clinical Pharmacology and Clinical Drug Development. These are currently available to students enrolled on King’s postgraduate taught programmes in Drug Development Science, and Clinical Pharmacology.